Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
ADHD Medications, Antidepressant Use Increasing in Youth with Type 1 Diabetes
October 3rd 2023A new study from Sweden is calling attention to disproportionate increases in psychotropic medication use among young people with type 1 diabetes relative to their counterparts without type 1 diabetes.
Read More
Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities
September 29th 2023A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.
Read More
Earlier bDMARD Initiation Can Prevent Long-Term Adverse Events in Juvenile Arthritis
September 25th 2023A study on juvenile idiopathic arthritis emphasizes early initiation of biologic treatment for better long-term outcomes, as delayed treatment is linked to greater physical disability and worse quality of life in adulthood.
Read More
Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data
September 25th 2023A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.
Read More
Type 1 and Type 2 Diabetes Incidence Increased During COVID-19 Pandemic
September 21st 2023An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.
Read More
Psoriasis Severity Could Signal Increased Cardiovascular Risk
September 21st 2023A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.
Read More
Patients with IBD More Likely to Develop Gout, Study Finds
September 20th 2023Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.
Read More
Abelacimab Demonstrates "Overwhelming" Efficacy vs Rivaroxaban in Phase 2b Trial
September 18th 2023Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.
Read More
Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH
September 15th 2023Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.
Read More
Empagliflozin Provides Consistent Benefit in HFrEF, Regardless of Diuretic Use
September 15th 2023Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.
Read More
Infliximab Biosimilars Show Promise, Equal Treatment Persistence in Treating IBD
September 14th 2023An analysis of the Phoenix cohort provides insight into responder rates and treatment persistence with infliximab biosimilars among those with no previous exposure to biologics, a previous failure to respond to biologics, or those switching from reference infliximab.
Read More
No Increase in Disease Activity, Treatment Discontinuation with Switch to Biosimilar Etancercept
September 13th 2023Use of etanercept biosimilars was not associated with an increased likelihood of treatment discontinuation or disease activity among people with rheumatoid arthritis relative to continuing treatment with originator etanercept.
Read More